Back
Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.
Journal article

Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.

  • Blackhall FH Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.
  • Peters S Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.
  • Bubendorf L Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.
  • Dafni U Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.
  • Kerr KM Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.
  • Hager H Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.
  • Soltermann A Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.
  • O'Byrne KJ Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.
  • Dooms C Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.
  • Sejda A Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.
  • Hernández-Losa J Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.
  • Marchetti A Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.
  • Savic S Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.
  • Tan Q Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.
  • Thunnissen E Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.
  • Speel EJ Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.
  • Cheney R Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.
  • Nonaka D Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.
  • de Jong J Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.
  • Martorell M Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.
  • Letovanec I Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.
  • Rosell R Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY.
  • Stahel RA Fiona H. Blackhall and Daisuke Nonaka, Manchester University and The Christie National Health Services Foundation Trust, Manchester; Keith M. Kerr, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Solange Peters and Igor Letovanec, Centre Hospitalier Universitaire Vaudois, Lausanne; Lukas Bubendorf and Spasenija Savic, Institute for Pathology, University Hospital Basel, Basel; Alex Soltermann and Rolf A. Stahel, University Hospital Zurich, Zurich, Switzerland; Urania Dafni, Frontier Science Foundation-Hellas and University of Athens, Athens, Greece; Henrik Hager, University Hospital, Aarhus, Denmark; Kenneth J. O'Byrne, St James's Hospital, Dublin, Ireland; Christoph Dooms, University Hospital KU Leuven, Leuven, Belgium; Aleksandra Sejda, Medical University of Gdansk, Gdansk, Poland; Javier Hernández-Losa, Vall d'Hebron University Hospital, Barcelona; Miguel Martorell, Universitat de Valencia and Hospital General Universitario de Valencia, Valencia; Rafael Rosell, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain; Antonio Marchetti, Center of Predictive Molecular Medicine, University Foundation, Chieti, Italy; Qiang Tan, Shanghai Lung Cancer Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Erik Thunnissen, VU University Medical Clinic Center; Jeroen de Jong, Netherlands Cancer Institute, Amsterdam; Ernst-Jan M. Speel, Maastricht University Medical Centre, Maastricht, the Netherlands; and Richard Cheney, Roswell Park Cancer Institute, Buffalo, NY. rolf.stahel@usz.ch.
Show more…
  • 2014-07-30
Published in:
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology. - 2014
Adenocarcinoma
Adenocarcinoma of Lung
Adult
Aged
Anaplastic Lymphoma Kinase
Cohort Studies
Europe
Female
Humans
Immunohistochemistry
In Situ Hybridization, Fluorescence
Lung Neoplasms
Male
Middle Aged
Neoplasm Staging
Prevalence
Receptor Protein-Tyrosine Kinases
Treatment Outcome
English PURPOSE
The prevalence of anaplastic lymphoma kinase (ALK) gene fusion (ALK positivity) in early-stage non-small-cell lung cancer (NSCLC) varies by population examined and detection method used. The Lungscape ALK project was designed to address the prevalence and prognostic impact of ALK positivity in resected lung adenocarcinoma in a primarily European population.


METHODS
Analysis of ALK status was performed by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) in tissue sections of 1,281 patients with adenocarcinoma in the European Thoracic Oncology Platform Lungscape iBiobank. Positive patients were matched with negative patients in a 1:2 ratio, both for IHC and for FISH testing. Testing was performed in 16 participating centers, using the same protocol after passing external quality assessment.


RESULTS
Positive ALK IHC staining was present in 80 patients (prevalence of 6.2%; 95% CI, 4.9% to 7.6%). Of these, 28 patients were ALK FISH positive, corresponding to a lower bound for the prevalence of FISH positivity of 2.2%. FISH specificity was 100%, and FISH sensitivity was 35.0% (95% CI, 24.7% to 46.5%), with a sensitivity value of 81.3% (95% CI, 63.6% to 92.8%) for IHC 2+/3+ patients. The hazard of death for FISH-positive patients was lower than for IHC-negative patients (P = .022). Multivariable models, adjusted for patient, tumor, and treatment characteristics, and matched cohort analysis confirmed that ALK FISH positivity is a predictor for better overall survival (OS).


CONCLUSION
In this large cohort of surgically resected lung adenocarcinomas, the prevalence of ALK positivity was 6.2% using IHC and at least 2.2% using FISH. A screening strategy based on IHC or H-score could be envisaged. ALK positivity (by either IHC or FISH) was related to better OS.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/141642
Statistics
Document views: 95 File downloads: